Samir Jabbour
Contact Info
Office Hours
- Today
- 7:30AM-5:00PM
Samir Jabbour
About Samir Jabbour
Dr. Jabbour graduated from the Faculty of Medicine at McGill University and completed his ophthalmology residency at the University of Montreal. He then pursued two years of advanced subspecialty training in Cornea, External Disease, and Refractive Surgery at two of the world's leading institutions: the Wilmer Eye Institute at Johns Hopkins School of Medicine in Baltimore, Maryland, and Moorfields Eye Hospital in London, United Kingdom. Additionally, he earned a Master’s in Public Health from Harvard University.
His research focuses primarily on ocular surface disease, keratoconus, and innovations in surgical techniques related to keratoplasty, cataract, and refractive surgery. Dr. Jabbour’s work has been published extensively in prestigious medical journals, and he is a frequent presenter at both national and international ophthalmology conferences. As the Director of the Cornea Fellowship Program at CHUM, he plays a pivotal role in training the next generation of corneal specialists. He also provides valuable instruction to medical students and ophthalmology residents from both the University of Montreal and McGill University.
Dr. Jabbour is an active member of the Board of Directors of the Canadian Ophthalmological Society and has made numerous media appearances—on television, radio, and in print—raising public awareness about ophthalmic diseases.
Select Your Region
Latin America
References
1. Patient Survey, STAAR Surgical ICL Data Registry, 2018
2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018
3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.
Important Safety Information
The EVO/EVO+ ICLs are indicated for patients who are 21 to 60 years of age and are available in spherical powers ranging from -3.0 D to -18.0 D for the correction/reduction of myopia with or without a cylinder power range from 1.0 D to 6.0 D. The hyperopic ICLs are indicated for patients who are 21 to 45 years of age and are available in powers ranging from +3.0 D to +10.0 D for the correction/reduction of hyperopia. In order to be sure that your surgeon will use an ICL with the most adequate power for your eye, your nearsightedness, farsightedness and astigmatism should be stable for at least a year before undergoing eye surgery. ICL surgery may improve your vision without eyeglasses or contact lenses. ICL surgery does not eliminate the need for reading glasses, even if you have never worn them before. ICL represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct your vision such as contact lenses and eye glasses. Implantation of an ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/ adverse reactions reported in conjunction with refractive surgery in general: additional surgeries, cataract formation, loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctiva I irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering ICL surgery you should have a complete eye examination and talk with your eye care professional about ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.